dc.contributor.author | Topuz, Erkan | |
dc.contributor.author | Tas, Faruk | |
dc.contributor.author | Derin, Duygu | |
dc.contributor.author | Camlica, Hakan | |
dc.contributor.author | Guney, Nese | |
dc.contributor.author | Aydiner, Adnan | |
dc.date.accessioned | 2021-03-03T11:25:27Z | |
dc.date.available | 2021-03-03T11:25:27Z | |
dc.date.issued | 2007 | |
dc.identifier.citation | Tas F., Derin D., Guney N., Camlica H., Aydiner A., Topuz E., "Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma", LUNG CANCER, cilt.57, sa.1, ss.79-83, 2007 | |
dc.identifier.issn | 0169-5002 | |
dc.identifier.other | av_27d00994-2460-4683-aca0-8595f97a11f3 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/31619 | |
dc.identifier.uri | https://doi.org/10.1016/j.lungcan.2007.02.009 | |
dc.description.abstract | Background: Topotecan is an active agent for the management of untreated and recurrent extensive-disease small cell tung cancer, (ED-SCLC). This study was designed to evaluate the efficacy and safety of a triplet combination with topotecan added to the standard PE regimen in previously untreated patients with ED-SCLC. | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Göğüs Hastalıkları ve Allerji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | SOLUNUM SİSTEMİ | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma | |
dc.type | Makale | |
dc.relation.journal | LUNG CANCER | |
dc.contributor.department | İstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü | |
dc.identifier.volume | 57 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 79 | |
dc.identifier.endpage | 83 | |
dc.contributor.firstauthorID | 183229 | |